Overview

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Status:
Enrolling by invitation

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia

Phase:

Phase 3

Details

Lead Sponsor:

Albireo